Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

Abstract The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR). Despite the initial response, disease progression invariably occurs. Although uncommon, BRAF V600E...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, João Victor Machado Alessi, Andrea Kazumi Shimada, José Flávio Gomes Marin, Anamaria Aranha Camargo, Artur Katz
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/44561a7f82f943959883dc09c9964b77
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44561a7f82f943959883dc09c9964b77
record_format	dspace
spelling	oai:doaj.org-article:44561a7f82f943959883dc09c9964b772021-12-02T16:06:10ZImpressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient10.1038/s41698-021-00149-42397-768Xhttps://doaj.org/article/44561a7f82f943959883dc09c9964b772021-02-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00149-4https://doaj.org/toc/2397-768XAbstract The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR). Despite the initial response, disease progression invariably occurs. Although uncommon, BRAF V600E mutation arises as a unique mechanism of resistance, and thus far, no prospective studies are available to support concurrent EGFR/BRAF blockade. We report a case of impressive radiological and ctDNA response under dabrafenib, trametinib, and osimertinib in an advanced EGFR-mutant lung adenocarcinoma patient who developed BRAF V600E as one of the acquired resistance mechanisms to second-line osimertinib. Moreover, the patient experienced remarkable clinical improvement and good tolerance to combination therapy. The present case suggests the importance of prospective studies evaluating both efficacy and safety of the combination in later line settings and points towards the potential of ctDNA to monitor resistance mechanisms and treatment benefit in clinical practice.Maurício Fernando Silva Almeida RibeiroFranciele Hinterholz KnebelFabiana BettoniRodrigo SaddiKarina Perez SacardoFelipe Sales Nogueira Amorim CanedoJoão Victor Machado AlessiAndrea Kazumi ShimadaJosé Flávio Gomes MarinAnamaria Aranha CamargoArtur KatzNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maurício Fernando Silva Almeida Ribeiro Franciele Hinterholz Knebel Fabiana Bettoni Rodrigo Saddi Karina Perez Sacardo Felipe Sales Nogueira Amorim Canedo João Victor Machado Alessi Andrea Kazumi Shimada José Flávio Gomes Marin Anamaria Aranha Camargo Artur Katz Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
description	Abstract The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR). Despite the initial response, disease progression invariably occurs. Although uncommon, BRAF V600E mutation arises as a unique mechanism of resistance, and thus far, no prospective studies are available to support concurrent EGFR/BRAF blockade. We report a case of impressive radiological and ctDNA response under dabrafenib, trametinib, and osimertinib in an advanced EGFR-mutant lung adenocarcinoma patient who developed BRAF V600E as one of the acquired resistance mechanisms to second-line osimertinib. Moreover, the patient experienced remarkable clinical improvement and good tolerance to combination therapy. The present case suggests the importance of prospective studies evaluating both efficacy and safety of the combination in later line settings and points towards the potential of ctDNA to monitor resistance mechanisms and treatment benefit in clinical practice.
format	article
author	Maurício Fernando Silva Almeida Ribeiro Franciele Hinterholz Knebel Fabiana Bettoni Rodrigo Saddi Karina Perez Sacardo Felipe Sales Nogueira Amorim Canedo João Victor Machado Alessi Andrea Kazumi Shimada José Flávio Gomes Marin Anamaria Aranha Camargo Artur Katz
author_facet	Maurício Fernando Silva Almeida Ribeiro Franciele Hinterholz Knebel Fabiana Bettoni Rodrigo Saddi Karina Perez Sacardo Felipe Sales Nogueira Amorim Canedo João Victor Machado Alessi Andrea Kazumi Shimada José Flávio Gomes Marin Anamaria Aranha Camargo Artur Katz
author_sort	Maurício Fernando Silva Almeida Ribeiro
title	Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
title_short	Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
title_full	Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
title_fullStr	Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
title_full_unstemmed	Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
title_sort	impressive response to dabrafenib, trametinib, and osimertinib in a metastatic egfr-mutant/braf v600e lung adenocarcinoma patient
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/44561a7f82f943959883dc09c9964b77
work_keys_str_mv	AT mauriciofernandosilvaalmeidaribeiro impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT francielehinterholzknebel impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT fabianabettoni impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT rodrigosaddi impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT karinaperezsacardo impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT felipesalesnogueiraamorimcanedo impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT joaovictormachadoalessi impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT andreakazumishimada impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT joseflaviogomesmarin impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT anamariaaranhacamargo impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient AT arturkatz impressiveresponsetodabrafenibtrametinibandosimertinibinametastaticegfrmutantbrafv600elungadenocarcinomapatient
_version_	1718385083374632960

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

Ejemplares similares